| Mississippi Eye Care Associates Of Jackson, Pllc | |
|
310 West Woodrow Wilson Avenue, Suite 300, Jackson, MS 39213-7662 | |
| (601) 366-9020 | |
| (601) 321-3979 |
| Full Name | Mississippi Eye Care Associates Of Jackson, Pllc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 310 West Woodrow Wilson Avenue, Jackson, Mississippi |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366697799 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 783 (Mississippi) | Primary |
| 332H00000X | Eyewear Supplier | 783 (Mississippi) | Secondary |
| Provider Name | Christopher T Bullin |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1457541450 PECOS PAC ID: 7214018621 Enrollment ID: I20080111000107 |
News Archive
A multi-institutional research collaborative has begun to decipher the complex interplay of genes that underlies the body's response to major injuries.
Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.
Life Technologies Corporation (NASDAQ:LIFE) today announced it has signed a definitive agreement to sell its ownership stake in its mass spectrometry business, operated as a joint venture, to Danaher Corporation (NYSE:DHR) for $450 million in cash. Danaher has also signed an agreement to acquire Life Technologies' joint venture partner in the mass spectrometry business, MDS Analytical Technologies, a division of MDS Inc. (NYSE:MDZ). The transaction is expected to close in the fourth quarter of 2009.
The collaboration will address a gap in analytical tests and standards applied for drugs based on glycoproteins, which now form the majority of approved biopharmaceutical drugs. Current analytical methods for characterizing glycans are time-consuming and difficult to deploy in commercial environments. They are also limited in their ability to detect and analyze minor glycan species.
› Verified 3 days ago
| Provider Name | Quatrisa Douglas Irving |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1821274648 PECOS PAC ID: 4284954629 Enrollment ID: I20150526001721 |
News Archive
A multi-institutional research collaborative has begun to decipher the complex interplay of genes that underlies the body's response to major injuries.
Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.
Life Technologies Corporation (NASDAQ:LIFE) today announced it has signed a definitive agreement to sell its ownership stake in its mass spectrometry business, operated as a joint venture, to Danaher Corporation (NYSE:DHR) for $450 million in cash. Danaher has also signed an agreement to acquire Life Technologies' joint venture partner in the mass spectrometry business, MDS Analytical Technologies, a division of MDS Inc. (NYSE:MDZ). The transaction is expected to close in the fourth quarter of 2009.
The collaboration will address a gap in analytical tests and standards applied for drugs based on glycoproteins, which now form the majority of approved biopharmaceutical drugs. Current analytical methods for characterizing glycans are time-consuming and difficult to deploy in commercial environments. They are also limited in their ability to detect and analyze minor glycan species.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mississippi Eye Care Associates Of Jackson, Pllc 310 West Woodrow Wilson Drive, Suite 300, Jackson, MS 39213-7662 Ph: (601) 366-9020 | Mississippi Eye Care Associates Of Jackson, Pllc 310 West Woodrow Wilson Avenue, Suite 300, Jackson, MS 39213-7662 Ph: (601) 366-9020 |
News Archive
A multi-institutional research collaborative has begun to decipher the complex interplay of genes that underlies the body's response to major injuries.
Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.
Life Technologies Corporation (NASDAQ:LIFE) today announced it has signed a definitive agreement to sell its ownership stake in its mass spectrometry business, operated as a joint venture, to Danaher Corporation (NYSE:DHR) for $450 million in cash. Danaher has also signed an agreement to acquire Life Technologies' joint venture partner in the mass spectrometry business, MDS Analytical Technologies, a division of MDS Inc. (NYSE:MDZ). The transaction is expected to close in the fourth quarter of 2009.
The collaboration will address a gap in analytical tests and standards applied for drugs based on glycoproteins, which now form the majority of approved biopharmaceutical drugs. Current analytical methods for characterizing glycans are time-consuming and difficult to deploy in commercial environments. They are also limited in their ability to detect and analyze minor glycan species.
› Verified 3 days ago
Envision Eye Care, Inc Optometrist Medicare: Medicare Enrolled Practice Location: 1316 North State Street, Jackson, MS 39202 Phone: 601-987-3937 Fax: 601-987-3922 | |
Medical Mall Vision Clinic Optometrist Medicare: Not Enrolled in Medicare Practice Location: 350 West Woodrow Wilson Ave, Suite 3110, Jackson, MS 39213 Phone: 601-366-9020 Fax: 601-321-3979 | |
Dr. Allen Dixon Findley, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2711 Greenway Dr, Suite A, Jackson, MS 39204 Phone: 601-922-9300 Fax: 601-922-6312 | |
Findley Vision, Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2711 Greenway Dr, Jackson, MS 39204 Phone: 601-922-9300 Fax: 601-922-6312 | |
Dellia Salone Evans, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1461 Canton Mart Rd Ste A, Jackson, MS 39211 Phone: 601-977-0835 Fax: 601-977-0689 | |
R. Kirk Smithhart, O.d. Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 500k E Woodrow Wilson Ave, Jackson, MS 39216 Phone: 601-366-4221 Fax: 601-362-3153 | |
Odoms Eye Care/optical Optometrist Medicare: Medicare Enrolled Practice Location: 1461 Canton Mart Rd Ste A, Jackson, MS 39211 Phone: 601-977-0835 Fax: 601-977-0689 |